Non-collagenous extracellular matrix protein dermatopontin may play a role as another component of transforming growth factor-β signaling pathway in colon carcinogenesis.
Colorectal cancer
Dermatopontin
Real-Time PCR
Sanger sequencing
TGF-β
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
ppublish
Résumé
Dermatopontin (DPT) is an extracellular matrix protein that plays roles in increasing the activity of transforming growth factor-β (TGF-β) and induction of cell quiescence. These roles suggest a tumor suppressor function for DPT. This study aimed to investigate changes in DPT gene expression in colorectal cancer providing a better understanding of its carcinogenesis. We used Matched Tumor/Normal Expression Array and Cancer Profiling Arrays I containing 34 and 7 cases of colorectal cancer and their matched controls, respectively, to test DPT expression. In addition, 38 newly diagnosed cases of colorectal cancer were enrolled and their fresh colonic tumoral and normal specimens were obtained. DPT mRNA expression was analyzed using real-time PCR. In cases with DPT under expression, exonic regions of the DPT gene were sequenced using the Sanger method. In array samples, DPT expression was decreased in 82.9% (34/41), increased in 12.2% (5/41), and had no changes in 4.9% (2/41). DPT was decreased in 14 fresh samples (36.8%), while 12 cases (31.6%) showed overexpression and the others had no changes. DPT expression showed no significant difference among various tumor grades and stages. The frequencies of DPT overexpression were higher in tumors having lymph node involvement (47.7% vs 28%, The similarities between changing patterns of DPT and TGF-β expression in colorectal cancer demonstrate that DPT may act as a pre-receptor component of the TGF-β signaling pathway in colon carcinogenesis.
Identifiants
pubmed: 34094025
doi: 10.22038/IJBMS.2021.46422.10720
pmc: PMC8143710
doi:
Types de publication
Journal Article
Langues
eng
Pagination
444-450Références
Trends Cell Biol. 2001 Nov;11(11):S44-51
pubmed: 11684442
Cancer Res. 1990 Jan 15;50(2):261-5
pubmed: 2295065
Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):549-54
pubmed: 7549813
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Oncotarget. 2014 Aug 30;5(16):6701-15
pubmed: 25149533
Fertil Steril. 2002 Jul;78(1):114-21
pubmed: 12095500
Biochem J. 1999 Feb 1;337 ( Pt 3):537-41
pubmed: 9895299
Exp Cell Res. 2004 Mar 10;294(1):30-8
pubmed: 14980498
World J Gastroenterol. 2007 Mar 14;13(10):1528-33
pubmed: 17461444
J Cell Sci. 1991 Jul;99 ( Pt 3):657-68
pubmed: 1939376
Ann Oncol. 2009 Mar;20(3):556-63
pubmed: 19073863
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
J Bone Miner Res. 2007 Sep;22(9):1338-49
pubmed: 17547532
Int J Cancer. 2012 Jun 15;130(12):2903-11
pubmed: 21796630
Genes Chromosomes Cancer. 2004 Jul;40(3):204-17
pubmed: 15139000
Biochemistry (Mosc). 2009 Sep;74(9):979-85
pubmed: 19916908
Cancer Lett. 2012 Jan 1;314(1):1-7
pubmed: 22018778
Connect Tissue Res. 2006;47(4):177-89
pubmed: 16987749
J Pathol. 2005 Jan;205(1):21-8
pubmed: 15586368
Fertil Steril. 2007 May;87(5):1166-72
pubmed: 17222838
J Biol Chem. 1989 Apr 5;264(10):5474-9
pubmed: 2925615
Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):249-58
pubmed: 20496531
Int J Mol Sci. 2019 Nov 20;20(23):
pubmed: 31756952
J Cancer Res Clin Oncol. 2015 Feb;141(2):229-35
pubmed: 25156818